Fluidigm Corporation (FLDM) Stake Boosted by Wells Fargo & Company MN

Wells Fargo & Company MN raised its position in shares of Fluidigm Corporation (NASDAQ:FLDM) by 15.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 25,521 shares of the medical research company’s stock after buying an additional 3,327 shares during the period. Wells Fargo & Company MN owned 0.09% of Fluidigm Corporation worth $146,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. FMR LLC acquired a new stake in Fluidigm Corporation during the fourth quarter worth approximately $1,165,000. Renaissance Technologies LLC boosted its stake in Fluidigm Corporation by 21.9% in the fourth quarter. Renaissance Technologies LLC now owns 451,300 shares of the medical research company’s stock worth $3,285,000 after buying an additional 81,000 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Fluidigm Corporation during the fourth quarter worth approximately $119,000. Finally, Norges Bank acquired a new stake in Fluidigm Corporation during the fourth quarter worth approximately $1,196,000. 91.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Fluidigm Corporation (NASDAQ FLDM) traded up 1.11% during midday trading on Friday, hitting $3.64. The stock had a trading volume of 240,868 shares. The stock’s market cap is $107.07 million. Fluidigm Corporation has a 52-week low of $2.52 and a 52-week high of $9.65. The firm has a 50 day moving average price of $3.70 and a 200-day moving average price of $4.85.

Fluidigm Corporation (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The firm had revenue of $23.90 million during the quarter, compared to the consensus estimate of $23.50 million. During the same quarter in the prior year, the firm earned ($0.63) EPS. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. Equities analysts predict that Fluidigm Corporation will post ($2.19) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/fluidigm-corporation-fldm-shares-bought-by-wells-fargo-company-mn-updated-updated-updated.html.

Several equities research analysts have recently issued reports on FLDM shares. Zacks Investment Research raised Fluidigm Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 1st. ValuEngine cut Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

In other Fluidigm Corporation news, insider Levin Capital Strategies, L.P. acquired 4,003,129 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was bought at an average price of $3.30 per share, for a total transaction of $13,210,325.70. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Evan/ Fa Jones sold 10,900 shares of the stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $4.54, for a total transaction of $49,486.00. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 4,106,038 shares of company stock valued at $13,496,083. Insiders own 4.70% of the company’s stock.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Institutional Ownership by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply